|
Thermo reversible hydrogel based delivery of mitomycin C for treatment of upper tract urothelial carcinoma (UTUC). |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Theracoat; Urogen pharma |
|
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Other Relationship - Altor BioScience |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - UroGen pharma |
Consulting or Advisory Role - UroGen pharma |
Research Funding - UroGen pharma |
Travel, Accommodations, Expenses - UroGen pharma |
|
|
Employment - UroGen pharma |
Leadership - UroGen pharma |
Research Funding - UroGen pharma |
Patents, Royalties, Other Intellectual Property - UroGen pharma |
Travel, Accommodations, Expenses - UroGen pharma |
|
|
Employment - UroGen pharma |
Leadership - UroGen pharma |
Research Funding - UroGen pharma |
Patents, Royalties, Other Intellectual Property - UroGen pharma |
Travel, Accommodations, Expenses - UroGen pharma |
|
|
Employment - UroGen pharma |
Research Funding - UroGen pharma |
Travel, Accommodations, Expenses - UroGen pharma |
|
|
Employment - UroGen pharma |
Research Funding - UroGen pharma |
Travel, Accommodations, Expenses - UroGen pharma |
|
|
Employment - UroGen pharma |
Research Funding - UroGen pharma |
Travel, Accommodations, Expenses - UroGen pharma |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - BioCancell; Ferring; Nucleix; Sitka; Taris BioMedical; Telesta Therapeutics; Urogen pharma; Vaxiion |
Research Funding - Endo Pharmaceuticals; FKD Therapies; JenaValve; Roche/Genentech; Viventia Biotech |
Travel, Accommodations, Expenses - BioCancell; Ferring; Oncogenex; Urogen pharma |